Share ownership Alnylam Pharmaceuticals, Inc.

ALNY

US02043Q1076

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 11:46:19 2026-06-10 am EDT			5-day change	1st Jan Change
296.48 ^USD	-0.40%		+1.03%	-25.66%

08:10am	Alnylam, Genesis Pharma Expand Commercial Partnership Into 4 Nordic Markets	MT
Jun. 09	Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11:20 AM

Share class: Alnylam Pharmaceuticals, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	133,512,573	133,266,670 ( 99.82 %)	0	99.82 %

Major shareholders: Alnylam Pharmaceuticals, Inc.

Name	Stocks	%	Valuation
Fidelity Management & Research Co. LLC 10.92 %	14,576,437	10.92 %	4 402 M $
Capital Research & Management Co. (World Investors) 8.091 %	10,802,348	8.091 %	3 262 M $
Capital Research & Management Co. (Global Investors) 7.094 %	9,471,181	7.094 %	2 860 M $
BlackRock Advisors LLC 6.26 %	8,357,377	6.26 %	2 524 M $
Vanguard Portfolio Management LLC 4.862 %	6,491,280	4.862 %	1 960 M $
JPMorgan Investment Management, Inc. 4.736 %	6,323,752	4.736 %	1 910 M $
Vanguard Capital Management LLC 4.454 %	5,946,706	4.454 %	1 796 M $
T. Rowe Price Investment Management, Inc. 3.89 %	5,193,324	3.89 %	1 568 M $
STATE STREET CORPORATION 2.489 %	3,322,698	2.489 %	1 003 M $
Geode Capital Management LLC 1.993 %	2,660,385	1.993 %	803 M $
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	85.84%
Others	9.25%
State Street Corp.	2.49%
Manulife Financial Corp.	0.5%
Schweizerische Nationalbank	0.29%
Individuals	0.26%
Sumitomo Mitsui Trust Group, Inc.	0.24%
Polar Capital Holdings Plc	0.19%
SEI Investments Co.	0.1%
Danske Bank A/S	0.05%
Swedbank AB	0.05%
Governments	0.04%
The Bank of Nova Scotia	0.01%
Silvercrest Asset Management Group, Inc.	0.01%
Fifth Third Bancorp	0.01%
Cullen/Frost Bankers, Inc.	0.01%
Unknown	0.66%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	78.86%
United Kingdom	9.03%
Canada	2.37%
Norway	1.8%
France	1.53%
Bermuda	1%
Switzerland	0.88%
Japan	0.6%
Australia	0.56%
Sweden	0.55%
South Korea	0.29%
Luxembourg	0.28%
Individuals	0.26%
Germany	0.22%
Ireland	0.22%
Denmark	0.18%
Netherlands	0.14%
China	0.14%
Singapore	0.07%
Hong Kong	0.06%
Finland	0.06%
Italy	0.06%
Austria	0.04%
Taiwan	0.02%
New Zealand	0.02%
Belgium	0.02%
Spain	0.02%
South Africa	0.02%
Poland	0.01%
India	0.01%
Cayman Islands	0.01%
Puerto Rico	0.01%

Based on 1000 largest holdings

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Companyâ€™s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Employees

2,500

Sector

Pharmaceuticals

More about the company